Premium
Inside Cover: From Antidiabetic to Antifungal: Discovery of Highly Potent Triazole–Thiazolidinedione Hybrids as Novel Antifungal Agents (ChemMedChem 12/2014)
Author(s) -
Wu Shanchao,
Zhang Yongqiang,
He Xiaomeng,
Che Xiaoying,
Wang Shengzheng,
Liu Yang,
Jiang Yan,
Liu Na,
Dong Guoqiang,
Yao Jianzhong,
Miao Zhenyuan,
Wang Yan,
Zhang Wannian,
Sheng Chunquan
Publication year - 2014
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201490045
Subject(s) - chemistry , thiazolidinedione , antifungal , rosiglitazone , triazole , moiety , candida albicans , combinatorial chemistry , stereochemistry , fluconazole , pharmacology , biochemistry , organic chemistry , biology , diabetes mellitus , microbiology and biotechnology , receptor , type 2 diabetes , endocrinology
The inside cover picture shows the design of potent triazole–thiazolidinediones (carbon atoms in green) as novel antifungal agents. Hybrid derivatives of known antidiabetic agent rosiglitazone (carbon atoms in cyan) and antifungal agent fluconazole (carbon atoms in yellow) were designed and evaluated again Candida albicans (top left), and modelling studies suggested key interactions between lanosterol 14α‐demethylase (CYP51; magenta) and the thiazolidinedione moiety. For more details, see the Full Paper by Wannian Zhang, Chunquan Sheng et al. on p. 2639 ff.